Johnson & Johnson clears a fresh record, shares near all-time high

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 11:59.

Johnson & Johnson (US4781601046) sits close to a new all-time high on the NYSE, with the stock recently trading around 254 dollars per share after touching 251.76 dollars at its latest record level according to Investing.com. Guggenheim has lifted its price target to 270 dollars and reaffirmed a Buy rating, citing stronger than expected prescription trends in key drugs.

What Guggenheim highlights

Guggenheim now expects Johnson & Johnson to deliver second-quarter 2026 revenues of 25.48 billion dollars and earnings per share of 2.87 dollars, ahead of consensus estimates at 24.96 billion dollars and 2.85 dollars per share. The firm continues to rate the shares Buy and names Johnson & Johnson as a top pick among large-cap biopharmaceutical stocks.

The analyst note points to robust prescriptions for Tremfya, Caplyta and Erleada as a key driver for the higher price target, indicating healthy demand across dermatology, neuropsychiatry and oncology segments. Johnson & Johnson is scheduled to report its second-quarter 2026 earnings on July 15, providing a near-term catalyst for investors focused on the pharma pipeline and margin dynamics.

Record levels and recent price action

According to Investing.com, Johnson & Johnson shares recently hit an all-time high at 251.76 dollars, reflecting a 1-year total return of 65.12 percent and a market capitalization of around 604.8 billion dollars. The shares currently trade just below that level, with a price of 251.18 dollars cited in the same report, only 0.97 percent under the 52-week high.

Additional data from Fidelity shows the stock at 254.66 dollars, up 3.99 percent or 9.78 dollars in the latest session, underlining the strong recent momentum in JNJ shares. Trading volume in the recent session reached more than 16.3 million shares, signaling solid liquidity and ongoing investor interest in the S&P 500 healthcare heavyweight.

The business behind the record

Johnson & Johnson’s current momentum is backed by several operational developments, notably a planned investment exceeding 1 billion dollars to enhance its Jacksonville, Florida operations for the Vision business. The initiative aims to expand manufacturing, packaging and distribution capacity for ACUVUE-brand contact lenses, supporting global demand for daily disposable and specialty lenses.

In medtech, Johnson & Johnson recently expanded U.S. availability of its TECNIS PureSee intraocular lens for cataract surgery patients, adding another option in its ophthalmology portfolio. On the pharmaceutical side, the company reported positive Phase 2/3 ENERGY study results for Imaavy, showing significant hemoglobin response in patients with warm autoimmune hemolytic anemia, which could support future revenue streams in rare diseases.

Long-term profile and upcoming earnings

Johnson & Johnson is a long-standing member of the Dow Jones Industrial Average and the S&P 500, with a diversified portfolio across pharmaceuticals, medical devices and consumer health products. The company’s historical focus on dividend stability and incremental earnings growth has made the stock a core holding in many income and healthcare-focused portfolios.

Consensus expectations compiled by Investing.com and other analyst platforms point to mid-single-digit revenue growth over the next few years, supported by immunology, oncology and neuroscience pipelines. The July 15 earnings release will give more detail on the traction of key products like Tremfya, Darzalex and Stelara, along with any updated commentary on legal provisions and capital allocation.

The product behind the stock

One representative product line for Johnson & Johnson is its ACUVUE contact lenses, including daily disposable variants designed for comfort and vision correction across myopia, hyperopia and astigmatism. The planned Jacksonville investment is explicitly linked to expanding ACUVUE manufacturing and distribution, highlighting the strategic weight of this consumer-facing medtech franchise.

Where the stock trades today

The Johnson & Johnson shares (US4781601046) trade on the NYSE at 254.66 dollars as of 2026-06-27, 00:59 EDT, based on Fidelity price data.

Disclaimer: This article provides factual information and context on Johnson & Johnson shares and does not contain investment advice, personal recommendations or solicitations to buy or sell securities. Data and prices are based on sources cited and may change over time.

en | US4781601046 | JOHNSON & JOHNSON | boerse | 69639237 | bgmi